Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Pharvaris N.V.NASDAQ: PHVS
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of €17.66M rose 79.3% year over year, ahead of the +31.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of €0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -3.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- €17.66M+11.9% QoQ
- Last fiscal yearDec 2025
- €45.34M-3.8% YoY
- LTMSep 2026
- €61.14M+31.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +79.3% | -100.0% | -179.3 pp |
| 1 year | -3.8% | -100.0% | -96.2 pp |
| 3-year CAGR | +15.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
EUR · from the income statement
- Latest · FY2025
- 45.34M EUR
- Year-over-year change
- -3.8%
- 4-year CAGR
- +25.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.34M | -3.8% |
| FY2024 | 2024-12-31 | 47.12M | +50.4% |
| FY2023 | 2023-12-31 | 31.34M | +6.8% |
| FY2022 | 2022-12-31 | 29.34M | +59.9% |
| FY2021 | 2021-12-31 | 18.35M | — |
Selling, General & Admin vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.2% is the 4th highest of 7, against a peer median of +68.3%.
- Over three fiscal years its annual growth of +15.6% compares with a peer median of +19.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $335.1B USD | +34325.1% | +15.8% | 32.6% | |
| LTM Sep 2026 | $376.47M USD | +23.4% | +19.5% | 57.8% | |
| LTM Jun 2026 | $337.33M USD | +6.9% | +29.8% | 35.9% | |
| LTM Mar 2026 | $236.26M USD | +113.2% | +19.5% | 64.0% | |
| LTM Jun 2026 | $153.89M USD | +144.6% | +66.0% | — | |
| LTM Sep 2026 | €61.14M EUR | +31.2% | +15.6% | — | |
| LTM Mar 2026 | $16.24M USD | -4.1% | -19.2% | 1893.0% | |
| Peer median (excluding PHVS) | — | +68.3% | +19.5% | 57.8% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Selling, General & Admin | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Operating Expenses | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| EBITDA | (42.31M) | (86.56M) | (99.57M) | (145.42M) | (173.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (54.14M) | (86.71M) | (96.91M) | (145.69M) | (169.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 268 | 16 | 0 | 5.47M | 0 |
| Interest Expense | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income / Expenses | 11.48M | 11.06M | (2.91M) | 13.29M | (3.89M) |
| Income Before Tax | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | (42.73M) | (76.33M) | (100.88M) | (134.22M) | (175.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| EPS (Diluted) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| Weighted Avg Shares | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
| Weighted Avg Shares (Diluted) | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.